Belimumab (GSK1550188) · Benlysta

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Systemic Lupus Erythematosus, Lupus Nephritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Sclerosis-Associated Interstitial Lung Disease

Also approved (2)
JP
  • Treatment of systemic lupus erythematosus in patients who have not responded sufficiently to conventional treatments
Product first approved 2017PMDA
EU
  • Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti‑dsDNA and low complement) despite standard therapy. Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA...
Product first approved 2011EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Systemic Lupus Erythematosus
NCT03747159 · Leiden University Medical Center
2018-10-01 – 2026-06-22 · Lupus Erythematosus, Systemic
What this study did
NCT05863936 · Nanjing University School of Medicine
2023-04-01 – 2024-12-31 · Lupus Nephritis, Remission, Safety Issues
What this study did
NCT01345253 · GlaxoSmithKline
2011-05-23 – 2018-09-21 · Systemic Lupus Erythematosus
What this study did
NCT00724867 · Human Genome Sciences Inc., a GSK Company
2008-08 – 2015-03 · Systemic Lupus Erythematosus
What this study did
Phase 2 (7)
Systemic Lupus Erythematosus
NCT02124798 · GlaxoSmithKline
2014-05-20 – 2015-04-13 · Systemic Lupus Erythematosus
What this study did
NCT00732940 · Human Genome Sciences Inc.
2008-10 – 2012-03 · Systemic Lupus Erythematosus
What this study did
Other / comorbidity
NCT07539857 · Leiden University Medical Center
2026-04-01 – 2030-01-01 · Kidney Transplant Rejection
What this study did
NCT06381453 · University Health Network, Toronto
2024-12-11 – 2029-04-30 · Autoimmune Hepatitis
What this study did
NCT05069051 · University Hospital Tuebingen
2022-01-19 – 2027-07-14 · Chronic Lymphoid Leukemia in Relapse
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05604742 · xuna
2022-01-01 – 2024-12-31 · cGVHD
What this study did
Phase 1 (5)
Systemic Lupus Erythematosus
NCT01894360 · GlaxoSmithKline
2013-10-14 – 2014-05-13 · Systemic Lupus Erythematosus
What this study did
NCT01516450 · GlaxoSmithKline
2011-12-26 – 2012-04-11 · Systemic Lupus Erythematosus
What this study did
Other / comorbidity
NCT04611971 · Janssen Research & Development, LLC
2020-10-27 – 2021-05-06 · Healthy
What this study did
Phase 4 (6)
Systemic Lupus Erythematosus
NCT06411249 · GlaxoSmithKline
2024-06-06 – 2029-07-30 · Systemic Lupus Erythematosus
What this study did
NCT03543839 · Northwell Health
2020-09-15 – 2029-03 · Lupus Erythematosus, Systemic, Lupus Erythematosus
What this study did
NCT04447053 · National University Hospital, Singapore
2021-11-08 – 2025-05-20 · Systemic Lupus Erythematosus
What this study did
NCT01705977 · GlaxoSmithKline
2012-11-27 – 2022-08-10 · Systemic Lupus Erythematosus
What this study did
NCT01597492 · Human Genome Sciences Inc., a GSK Company
2012-05-31 – 2015-09-24 · Systemic Lupus Erythematosus
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT03154385 · Assistance Publique - Hôpitaux de Paris
2017-03-13 – 2019-11-13 · Immune Thrombocytopenia
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Systemic Lupus Erythematosus

Competitive landscape

This drug's own stage for Lupus Nephritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Belimumab (GSK1550188) (Benlysta): this drugApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Reliable signalNo reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Voclosporin (Lupkynis)ApprovedSmall moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signal
NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%)
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
Rapcabtagene AutoleucelPhase 2UndisclosedCD19not yet gradedNo reviewed efficacy summary in this indication
SHR-2173Phase 2UndisclosedIFNAR1 / TACInot yet gradedNo reviewed efficacy summary in this indication
VonsetamigPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Benlysta (Belimumab (GSK1550188)) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 4Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-06-29 · NCT06411249 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 2Kidney Transplant RejectionRecruiting
Est. primary completion 2028-01-01 · NCT07539857 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Autoimmune HepatitisRecruiting
Est. primary completion 2028-04-30 · NCT06381453 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-09 · NCT03543839 · CT.gov ↗
What to watch

See the full readout calendar ↗